Q3 EPS Estimate for Promis Neurosciences Lifted by Analyst

Promis Neurosciences (NASDAQ:PMN) – Analysts at HC Wainwright upped their Q3 2026 earnings estimates for shares of Promis Neurosciences in a note issued to investors on Monday, October 12th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.98) per share for the quarter, up from their previous estimate of ($1.13). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Promis Neurosciences’ current full-year earnings is ($5.29) per share. HC Wainwright also issued estimates for Promis Neurosciences’ Q4 2026 earnings at ($0.86) EPS, FY2026 earnings at ($4.18) EPS, Q1 2027 earnings at ($0.68) EPS, Q2 2027 earnings at ($0.60) EPS, Q3 2027 earnings at ($0.65) EPS, Q4 2027 earnings at ($0.71) EPS and FY2027 earnings at ($2.63) EPS.

Promis Neurosciences (NASDAQ:PMN) last released its quarterly earnings results on Thursday, August 13th. The company reported ($1.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.38) by $0.10.

Several other analysts also recently weighed in on the company. Cantor Fitzgerald began coverage on Promis Neurosciences in a research note on Tuesday, June 30th. They set an “overweight” rating on the stock. Guggenheim reiterated a “buy” rating and set a $69.00 price target (up from $35.00) on shares of Promis Neurosciences in a research report on Tuesday, July 28th. Roth Capital set a $29.00 price target on Promis Neurosciences in a research note on Friday, August 21st. Weiss Ratings reissued a “sell (e+)” rating on shares of Promis Neurosciences in a report on Tuesday, September 8th. Finally, Chardan Capital set a $20.00 price target on Promis Neurosciences and gave the company a “buy” rating in a report on Monday, July 27th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $34.00.

Promis Neurosciences Price Performance

Shares of PMN stock opened at $8.66 on Wednesday. Promis Neurosciences has a 12-month low of $6.27 and a 12-month high of $27.40. The business has a 50 day simple moving average of $12.78 and a 200 day simple moving average of $12.13.

Institutional Trading of Promis Neurosciences

A number of institutional investors have recently made changes to their positions in the stock. Janus Henderson Group PLC bought a new stake in Promis Neurosciences during the first quarter worth approximately $16,418,000. Yu Fan acquired a new stake in Promis Neurosciences in the first quarter worth approximately $4,188,000. Ally Bridge Group NY LLC boosted its stake in Promis Neurosciences by 66.1% during the 1st quarter. Ally Bridge Group NY LLC now owns 414,219 shares of the company’s stock valued at $5,261,000 after purchasing an additional 164,880 shares in the last quarter. ADAR1 Capital Management LLC bought a new position in Promis Neurosciences during the 1st quarter valued at $1,211,000. Finally, Seven Fleet Capital Management LP bought a new position in Promis Neurosciences during the 1st quarter valued at $135,000. 50.13% of the stock is owned by institutional investors and hedge funds.

About Promis Neurosciences

ProMIS Neurosciences Inc (NASDAQ: PMN) is a clinical-stage biotechnology company focused on developing antibody-based treatments for neurodegenerative diseases. The company uses its proprietary technology platform to identify disease-related misfolded proteins and selectively target toxic forms that may contribute to neuronal damage.

ProMIS’s lead investigational product is PMN310, an antibody designed to target toxic soluble amyloid-beta oligomers associated with Alzheimer’s disease while avoiding healthier forms of amyloid-beta.